<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680859</url>
  </required_header>
  <id_info>
    <org_study_id>7 DK GpR3</org_study_id>
    <secondary_id>U01DK073983</secondary_id>
    <secondary_id>U01DK112193</secondary_id>
    <secondary_id>U01DK073975</secondary_id>
    <secondary_id>U01DK074035</secondary_id>
    <secondary_id>U01DK074007</secondary_id>
    <secondary_id>U01DK073974</secondary_id>
    <secondary_id>U24DK074008</secondary_id>
    <nct_id>NCT03680859</nct_id>
  </id_info>
  <brief_title>Gastroparesis Registry 3</brief_title>
  <acronym>GpR3</acronym>
  <official_title>The NIDDK Gastroparesis Registry 3: Characterization and Clinical Course of Symptoms and Gastric Emptying in Patients With Symptoms of Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to create a new registry of patients with gastroparesis in order&#xD;
      to better understand the characteristics of patients with gastroparesis and follow how their&#xD;
      condition changes over time. The data collected may improve the understanding of the&#xD;
      condition to enable better diagnosis and treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GpR 3 is an observational study of patients with symptoms of gastroparesis with either&#xD;
      delayed or normal gastric emptying. Epidemiological, clinical, physiological, and patient&#xD;
      outcome data will be collected to characterize the patients and their clinical course to&#xD;
      better understand this disorder. The long-term goal is to help phenotype patients into&#xD;
      pathophysiologically defined subsets. This classification will provide a foundation for&#xD;
      translational research, facilitating the search for etiopathogenesis and enhance the ability&#xD;
      to define and conduct large clinical trials, ultimately leading to the development of more&#xD;
      rational and effective therapeutic approaches for gastroparesis.&#xD;
&#xD;
      The primary objectives of the Gastroparesis Registry 3 (GpR 3) are:&#xD;
&#xD;
        -  To create a new registry of patients with symptoms of gastroparesis, both patients with&#xD;
           delayed gastric emptying and patients with similar symptoms but normal gastric emptying,&#xD;
           for the enhanced study of symptoms, gastric motility abnormalities, patient&#xD;
           characteristics, and degree of morbidity.&#xD;
&#xD;
        -  To follow a well-characterized cohort to further define the natural history and clinical&#xD;
           course of patients with symptoms of gastroparesis - both symptoms and gastric emptying&#xD;
           over time. Treatments given for their clinical care and clinical responses to treatments&#xD;
           will be recorded.&#xD;
&#xD;
        -  To provide a reliable source for recruitment of well-characterized patients with&#xD;
           gastroparesis for other studies including therapeutic clinical trials,&#xD;
           pathophysiological, molecular, histopathologic, or other ancillary studies. These&#xD;
           subsequent clinical trials or ancillary studies will be conducted under separate study&#xD;
           protocols with separate consent processes.&#xD;
&#xD;
      Specific secondary objectives of GpR3 have been developed to allow the patients entered in&#xD;
      GpR3 to help advance our understanding of gastroparesis:&#xD;
&#xD;
        -  Assess several areas of gastric motility in patients with symptoms of gastroparesis&#xD;
           (fundic accommodation, antral contractility, global gastric emptying).&#xD;
&#xD;
        -  Determine the change in gastric motility over time, in patients with gastroparesis and&#xD;
           in patients with symptoms of gastroparesis but normal gastric emptying.&#xD;
&#xD;
        -  Evaluate the clinical symptomatic course (outcome) of patients followed in the registry.&#xD;
&#xD;
        -  Use the registry to better capture clinical treatment responses to specific treatments&#xD;
           while patients are in the registry.&#xD;
&#xD;
        -  Characterize abdominal pain in patients with gastroparesis and gastroparesis-like&#xD;
           syndrome by:&#xD;
&#xD;
             -  Describing the abdominal pain seen in patients with gastroparesis&#xD;
&#xD;
             -  Determining if the pain has neuropathic or nociceptive qualities&#xD;
&#xD;
             -  Determining attributes of patients with abdominal pain&#xD;
&#xD;
             -  Assessing patients in the presence of sensory gastric dysfunction&#xD;
&#xD;
             -  Objective mapping of the abdominal pain and determining central and/or peripheral&#xD;
                attributes of the abdominal pain&#xD;
&#xD;
        -  Compare the Rome IV categories of gastric disorders (functional dyspepsia (FD),&#xD;
           epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), chronic idiopathic&#xD;
           nausea and vomiting (CINV), rumination syndrome, cyclic vomiting syndrome, central&#xD;
           abdominal pain syndrome) to our present classification of gastroparesis and&#xD;
           gastroparesis-like disorder.&#xD;
&#xD;
        -  Determine the prevalence of hypermobility spectrum disorders (HSD) in patients with&#xD;
           gastroparesis.&#xD;
&#xD;
        -  Compare the water load satiety test (WLST) to intragastric meal distribution (IMD)&#xD;
           during scintigraphy and to symptoms of early satiety, postprandial fullness in patients&#xD;
           with symptoms of gastroparesis.&#xD;
&#xD;
        -  Collect serum, plasma, and peripheral blood mononuclear cells (PBMC) that can be used&#xD;
           for subsequent analysis to address specific research questions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline GSCI score at 48 weeks</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The outcome is assessed using the self-reported postprandial fullness/early satiety subscore, which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 48-weeks minus the baseline subscore.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Short Form Health Survey (SF-36v2) physical health QOL component score at 48 weeks</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) physical health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 48-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Short Form Health Survey (SF-36v2) mental health QOL component score at 48 weeks</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) mental health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 48-weeks minus the baseline score.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetic Gastroparesis</condition>
  <condition>Idiopathic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Diabetic</arm_group_label>
    <description>Participants with a primary etiology of diabetic gastroparesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic</arm_group_label>
    <description>Participants with a primary etiology of idiopathic gastroparesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-fundoplication</arm_group_label>
    <description>Participants with a primary etiology of post-Nissen fundoplication gastroparesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic with Normal Emptying</arm_group_label>
    <description>Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic with Normal Emptying</arm_group_label>
    <description>Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-fundoplication with Normal Emptying</arm_group_label>
    <description>Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, and PBMC specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females at least 18 years old at the initial screening interview in the United&#xD;
        States who are:&#xD;
&#xD;
          -  Diabetic, idiopathic, or post-fundoplication gastroparesis patients with delayed&#xD;
             gastric emptying&#xD;
&#xD;
          -  Diabetic, idiopathic, or post-fundoplication patients with symptoms of gastroparesis&#xD;
             but with normal gastric emptying&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms of gastroparesis of at least 12 weeks' duration with varying degrees of&#xD;
             nausea, vomiting, early satiety, postprandial fullness&#xD;
&#xD;
          -  An etiology of either diabetic, idiopathic, or post-fundoplication (Nissen, Dor, or&#xD;
             Toupet) gastroparesis or gastroparesis-like disorder (symptoms of gastroparesis but&#xD;
             normal gastric emptying)&#xD;
&#xD;
          -  Gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or&#xD;
             equivalent generic liquid egg white meal) within the last 6 months with either:&#xD;
&#xD;
          -  Abnormal gastric emptying rate defined as an abnormal 2 hour (&gt;60% retention) and/or 4&#xD;
             hour (&gt;10% retention) result based on a 4 hour scintigraphic gastric emptying study.&#xD;
             (This group will comprise ~75% of patients in the registry.)&#xD;
&#xD;
          -  Patients with a normal gastric emptying rate, but who have symptoms of gastroparesis.&#xD;
             (This group will comprise ~25% of patients in the registry.)&#xD;
&#xD;
          -  Negative upper endoscopy or upper radiographic GI series within 2 years of&#xD;
             registration&#xD;
&#xD;
          -  Age at least 18 years at initial screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comply with or complete the gastric emptying test by scintigraphy&#xD;
             (including allergy to eggs)&#xD;
&#xD;
          -  Use of narcotic analgesics greater than three days per week&#xD;
&#xD;
          -  Presence of other conditions that could explain the patient's symptoms:&#xD;
&#xD;
          -  Pyloric or intestinal obstruction: by EGD, UGI, or Abdominal CT&#xD;
&#xD;
          -  Active inflammatory bowel disease&#xD;
&#xD;
          -  Known eosinophilic gastroenteritis or eosinophilic esophagitis&#xD;
&#xD;
          -  Primary neurological conditions that can cause nausea and vomiting such as increased&#xD;
             intracranial pressure, space occupying or inflammatory/infectious lesions&#xD;
&#xD;
          -  Acute renal failure&#xD;
&#xD;
          -  Chronic renal failure (serum creatinine &gt;3 mg/dL) and/or on hemodialysis or peritoneal&#xD;
             dialysis&#xD;
&#xD;
          -  Acute liver failure&#xD;
&#xD;
          -  Advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7)&#xD;
&#xD;
          -  Prior gastric surgery including total or subtotal (near complete) gastric resection,&#xD;
             esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty,&#xD;
             pyloromyotomy. Note: patients with prior Nissen, Dor, or Toupet fundoplication will be&#xD;
             eligible for enrollment.&#xD;
&#xD;
          -  Any other condition, which in the opinion of the investigator, could explain the&#xD;
             symptoms or interfere with study requirements&#xD;
&#xD;
          -  Inability to obtain informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Serrano, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Hamilton, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Parkman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Temple University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Braden Kuo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Miriel</last_name>
    <phone>410-955-4165</phone>
    <email>laura.miriel@jhu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Abell, MD</last_name>
      <phone>502-852-7963</phone>
      <email>thomas.abell@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bridget Cannon</last_name>
      <phone>(502) 540-1428</phone>
      <email>Bridget.cannon@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Abell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankaj Pasricha, MD</last_name>
      <phone>410-550-6871</phone>
      <email>ppasric1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Burns</last_name>
      <phone>(410) 550-6871</phone>
      <email>rburns22@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pankaj J Pasricha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital-Digestive Healthcare Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Braden Kuo, MD</last_name>
      <phone>617-726-0196</phone>
      <email>bkuo@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Konkel</last_name>
      <phone>(617) 726-0196</phone>
      <email>hkonkel@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth L Koch, MD</last_name>
      <phone>336-713-7333</phone>
      <email>kkoch@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anya Brown</last_name>
      <phone>(336) 716-4325</phone>
      <email>anybrown@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth L Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry P Parkman, MD</last_name>
      <phone>215-707-7579</phone>
      <email>henry.parkman@temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Paul Silver</last_name>
      <phone>(800) 836-7536</phone>
      <email>paul.silver@temple.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry P Parkman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center (TTUHSC)</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Sarosiek, MD</last_name>
      <phone>915-545-6626</phone>
      <phone_ext>230</phone_ext>
      <email>irene.sarosiek@ttuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denise Vasquez</last_name>
      <phone>(915) 214-4388</phone>
      <email>denise.vasquez@ttuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard W McCallum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://jhuccs1.us/gpcrc/</url>
    <description>Gastroparesis Clinical Research Consortium</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public use complete database will be submitted to the NIDDK Data Repository</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>By the end of the funding period</ipd_time_frame>
    <ipd_access_criteria>An investigator interested in acquiring GpR3 study data should contact the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository at https://www.niddkrepository.org/search/study/ and apply to obtain the data required for their study. IRB approval</ipd_access_criteria>
    <ipd_url>http://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

